Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant mFOLFOXIRI for EMVI-positive locally advanced rectal cancer
ChiCTR1800019986Phase 2Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jan 2019
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluorouracil, folinic acid, oxaliplatin and irinotecan in rectal adenocarcinoma, sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Metastasis-free survival. Started Jan 2019; status: recruiting.
02
Drugs
fluorouracilfolinic acidoxaliplatinirinotecan
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR1800019986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019986.